Johnson & Johnson Showcases Innovation and Commitment to People Living With GMG, Presenting 25 Abstracts at AANEM Annual Meeting and MGFA Scientific Session
October 04, 2024
October 04, 2024
NEW BRUNSWICK, New Jersey, Oct. 4 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
- Oral session, featuring nipocalimab results in adolescents living with gMG represents first FcRn blocker data to be presented focusing on this population with high unmet medical need
- Oral and poster sessions to include multiple new analyses from the Phase 3 Vivacity-MG3 pivotal study in adults living with gMG that reinforce the potential of nipocal . . .
* * *
- Oral session, featuring nipocalimab results in adolescents living with gMG represents first FcRn blocker data to be presented focusing on this population with high unmet medical need
- Oral and poster sessions to include multiple new analyses from the Phase 3 Vivacity-MG3 pivotal study in adults living with gMG that reinforce the potential of nipocal . . .